The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Here's an interesting one from Munira Wilson Lib Dem Twickenham
Question 10673
To ask the Secretary of State for Health and Social Care, what steps his Department has put in place to prevent the input of faked Lateral Flow Test results taken at home into the NHS Covid app.
Jo Churchill (Bury St Edmunds)
Answer: The NHS COVID-19 app allows users to manually enter a positive test result from a lateral flow device (LFD) test. If a user’s LFD test is positive and they report the result as advised in the pack, they will receive a separate text and/or email with a one-off code, to enter in the app. This will trigger the user’s self-isolation countdown timer and allow them to book their confirmatory laboratory test via the app. Users cannot enter a negative LFD test result into the app as codes are not sent out for these results.
The one-off eight digit code for a positive test can only be created following receipt of a valid LFD test ID number linked to the specific valid positive test result.
The question obviously sought to find out about the possibility of faking negative results but the answer only refers to positives. Why would anyone want to fake a positive result (unless to claim benefits once furlough ends I guess.) The more important question about fake negatives remains unanswered. (Typical.)
Philip Davies (Shipley) Asks
Question 10264: To ask the Secretary of State for Health and Social Care, for what reason Surescreen Diagnostics has been awarded a contract for 24 months until January 2023 for the manufacture of lateral flow antigen tests for SARS-CoV-2 in the context of the potential removal of legal limits on social contact on 21 June 2021 as set out in the Government's roadmap out of lockdown.
Jo Churchill (Bury St Edmunds)
A: This contract was awarded in January 2021, before the current lockdown easing measures were announced. The contract is flexible and does not contain committed volumes of purchasing of tests. We are able to alter the amount of tests bought through this contract on a monthly basis and have the necessary contract clauses to exit the contract at short notice if required.
The contract was awarded under Regulation 32 measures in procurement procedures, based on the urgent nature of the requirement for lateral flow antigen tests and the lack of sovereign capability to produce these products in the United Kingdom. Worldwide manufacturers with tests validated for use in the UK were invited to make manufacturing proposals, including licencing production and were evaluated on the basis of a range of criteria including cost, performance and location/ability to provide security of supply.
Philip Davies (Shipley) Asks
Question 10265: To ask the Secretary of State for Health and Social Care, how Surescreen Diagnostics was awarded a contract for 24 months until January 2023 for the manufacture of Lateral Flow Antigen tests for SARS-CoV-2; where and how that contract was advertised; and what criteria were used to select that company.
Jo Churchill (Bury St Edmunds)
A: This contract was awarded in January 2021, before the current lockdown easing measures were announced. The contract is flexible and does not contain committed volumes of purchasing of tests. We are able to alter the amount of tests bought through this contract on a monthly basis and have the necessary contract clauses to exit the contract at short notice if required.
The contract was awarded under Regulation 32 measures in procurement procedures, based on the urgent nature of the requirement for lateral flow antigen tests and the lack of sovereign capability to produce these products in the United Kingdom. Worldwide manufacturers with tests validated for use in the UK were invited to make manufacturing proposals, including licencing production and were evaluated on the basis of a range of criteria including cost, performance and location/ability to provide security of supply.
Some but not all of the awkward questions tabled by Philip Davies have now been answered.
Philip Davies (Shipley) Asked
Question 10260: To ask the Secretary of State for Health and Social Care, whether his Department has entered into any contracts for the provision of rapid covid-19 tests with organisations that are not members of the UK Rapid Antigen Test Consortium.
Jo Churchill (Bury St Edmunds)
Answer: The Department has entered into contracts with Innova for the provision of self-test lateral flow devices (LFDs) and Innova, Abbott and Orient Gene, through their distributor Tanner Pharma, for the provision of assisted LFDs.